Moreover, AML-MSCs possess an enhanced capacity to support hematopoiesis due to an abnormal expression of cell surface molecules, such as CD44, CD49e, CD271, and CXCL12 [128,129]. The gene discussed is CD44; the disease is acute myeloid leukemia.